血清CA125值与胰腺癌高剂量少分次放射治疗预后关系的研究

摘要

Objective:To investigate the predictive value of serum CA125 values to hypofraction radiotherapy for patients with stage III pancreatic cancer.Methods: 82 patients were selected whose primary diagnosis were stage III pancreatic cancer, including 39 cases of male and 43 cases of female. The median age was 60 years. They were examined by serum CA125 and CA19-9 before radiotherapy. The dose mode of radiotherapy was 50Gy for PTV and 65-70Gy for GTV in 15-20 fractions. Survival differences were compared with Log-rank test and Kaplan-Meier test, using Cox model for multiple factors analysis.Results: Median survival time (MST) was 12 months. MST of abnormal CA125 group was 11 months and MST of normal group was 14 months. Survival analysis showed that CA125 value was associated with overall survival (P=0.015). CA19-9 value had no correlation with total survival time statistically (P>0.05). Serum CA125 value before radiotherapy was an independent prognosis factor for total survival time by multifactor analysis.Conclusion: Serum CA125 value has important prognosis value for pancreatic cancer with hypofraction radiotherapy.%目的：探讨胰腺癌患者血清CA125值对高剂量少分次放射治疗生存时间的预测作用。方法：选取初诊的82例Ⅲ期胰腺癌患者，其中男性39例，女性43例，中位年龄60岁；放射治疗前均行血清CA125和CA19-9检查；处方剂量计划靶区容积(PTV)50 Gy，肿瘤体积(GTV)65～70 Gy，15～20分次。82例患者入组，生存期的评估采用Kaplan-Meier法，生存差异的比较采用Log-rank检验，Cox模型行多因素分析。结果：中位总生存时间为12个月。CA125异常组中位生存时间为11个月，正常组中位生存时间为14个月，生存分析显示CA125与总生存时间有关，CA19-9与总生存时间的统计学无相关性，多因素分析显示放射治疗前CA125为患者总生存时间的独立预后因素。结论：血清CA125水平在预测胰腺癌高剂量少分次放射治疗生存时间方面有重要价值。